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Genotype and phenotype 
correlation of calcium-sensing 
receptor variants
AWC Kung1
Mutations of the calcium-sensing receptor (CaR) gene give rise to 
disorders of renal calcium excretion. It is now demonstrated that even 
common variants of CaR can cause alteration in tissue sensitivity to 
extracellular calcium and are associated with primary hypercalciuria. 
Agents targeting these functional domains may well be an option for the 
management of hypercalciuria and renal stones.
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Th e extracellular calcium-sensing recep-
tor (CaR) plays a key role in maintaining 
extracellular calcium homeostasis. It ena-
bles several tissues involved in this process 
to detect minute changes in extracellular 
Ca2+ and respond with an alteration in the 
cellular function to restore extracellular 
Ca2+ to the normal range. CaR is a member 
of group II within family C of the super-
family of G protein-coupled receptors.1 
Structurally, CaR is a fusion protein that 
consists of an external milieu and trans-
membrane and intracellular domains that 
participate in signal transduction. CaR was 
initially cloned from the parathyroid gland 
and was subsequently identifi ed in tissues 
that participate in the regulation of Ca2+ 
homeostasis, including calcitonin-secret-
ing C cells of the thyroid gland, kidney 
cells, and also bone and intestinal cells.1 
Th e sensing of low extracellular Ca2+ by 
CaR evokes parathyroid hormone (PTH) 
secretion by the parathyroid glands. PTH 
acts on the kidneys to mediate a number of 
physiological activities, including promo-
tion of distal tubular calcium reabsorption, 
enhancement of phosphaturia, and stimu-
lation of conversion of 25-hydroxyvitamin 
D3 to the active form 1,25-dihydroxyvita-
min D3. Increased 1,25-dihydroxyvitamin 
D3 production enhances gastrointestinal 
calcium absorption, which synergizes with 
PTH to mobilize calcium release from the 
skeleton. Together with increased renal 
tubular calcium reabsorption, movement 
of calcium into the extracellular fl uid from 
the gastrointestinal tract and bone helps to 
normalize extracellular Ca2+ levels.
CaR is expressed in various parts of the 
renal tubules, including the apical mem-
brane of the proximal tubule, the baso-
lateral membrane of the medullary thick 
ascending limb, the cortical thick ascend-
ing limb, the distal convoluted tubules, and 
the apical surface of the inner medullary 
collecting duct. In the kidney, CaR medi-
ates several functions: it reduces the phos-
phaturic action of PTH in the proximal 
tubule, and it inhibits the reabsorption of 
salt in the medullary thick ascending limb 
and cortical thick ascending limb, and the 
reabsorption of calcium in the distal con-
voluted tubule. It also reduces the reab-
sorption of calcium and magnesium in the 
cortical thick ascending limb and inhibits 
vasopressin-stimulated water reabsorption 
in the inner medullary collecting duct to 
limit the urine-concentrating ability.2
Since the fi rst cloning of CaR in bovine 
parathyroid tissue,1 a number of inactivat-
ing and activating mutations of CaR have 
been described (Figure 1). Inactivating 
mutations of CaR, characterized by resist-
ance to extracellular Ca2+, were shown to 
be associated with two hypercalcemic 
disorders, familial hypocalciuric hyper-
calcemia and neonatal severe primary 
hyperparathyroidism. Activating muta-
tions of CaR, characterized by increased 
sensitivity to extracellular Ca2+, are linked 
to autosomal-dominant and sporadic 
hypocalcemia. Subjects with inactivat-
ing mutations of CaR exhibit absolute or 
relative hypocalciuria due to diminished 
hypercalcemia-induced calciuresis in the 
distal renal tubules, whereas subjects with 
activating mutations of CaR have reduced 
parathyroid set point and excessive renal 
calcium excretion despite hypocalcemia.2 
Th ese mutations and inherited disorders 
of CaR are rare but allow the understand-
ing that the extracellular calcium ion can 
serve as an extracellular fi rst messenger 
for CaR.
Perhaps more interesting are the recent 
observations of the association of com-
mon polymorphisms of CaR with renal 
calcium excretion in the general popu-
lation. Vezzoli et al.3 (this issue) report 
that the single-nucleotide polymorphism 
at nucleotide position 2968 (amino acid 
position 990) is associated with primary 
hypercalciuria.3 Vezzoli et al.3 studied 
three single-nucleotide polymorphisms at 
the intracytoplasmic tail of CaR: G2956T, 
C3031G, and A2968G, which are in high 
linkage disequilibrium with each other 
(Figure 1). Their results show that the 
variant G allele of A2968G, which results 
in replacement of arginine with glycine 
(R990G), was associated with an increased 
risk of hypercalciuria. Women with pri-
mary hypercalciuria but a negative history 
of kidney stones had a higher frequency of 
the 990G variant allele, and homozygous 
or heterozygous carriers of this allele had 
a 5.2-fold increased risk of hypercalciuria 
when compared with homozygous carri-
ers of the wild-type allele. Vezzoli et al.3 
also confi rmed that the 990G variant allele 
was associated with a gain of function of 
the CaR. Th is was evidenced by a lower 
extracellular Ca2+ concentration needed 
to produce the half-maximal intracellular 
Ca2+ response in human embryonic kid-
ney (HEK-293) cells transfected with the 
990G allele. With the use of the bioinfor-
matics approach, it was predicted that the 
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substitution of arginine with glycine would 
cause a signifi cant alteration in the second-
ary structure of the CaR protein.
This 990G allele has previously been 
reported to be associated with hypercalci-
uria and calcium stone forms with or with-
out the presence of primary or secondary 
hyperparathyroidism,4–9 although other 
studies failed to confi rm these associa-
tions.10,11 It is not certain whether sporadic 
cases of primary hypercalciuria without 
stone formation, and hypercalciuria with 
nephrolithiasis with or without hyper-
parathyroidism, represent a continuum 
of one single disorder. Because of the low 
frequency of the 990G allele, most studies 
are unable to address the dose-dependent 
eff ect of this allele. In reports of hypercal-
ciuria and nephrolithiasis with or without 
hyperparathyroidism, the 990G allele was 
associated with lower levels of PTH and/or 
serum calcium, suggesting that the vari-
ant receptor had increased sensitivity to 
extracellular Ca2+ in both parathyroid and 
kidney tubules. However, in the study by 
Vezzoli et al.3, women carrying the 990G 
allele only had hypercalciuria with nor-
mal serum calcium and PTH levels. Th e 
variable response in serum calcium and 
PTH in these diff erent reports suggests 
that the tissue sensitivity of 990G in the 
kidney tubules may diff er from that in the 
parathyroid tissues. It remains to be con-
fi rmed whether the expression level of this 
990G allele may diff er between the kidney 
tubules and parathyroid cells, as well as 
between the bone and intestinal cells. It 
is also likely that this variant allele might 
aff ect interaction of CaR with diff erent 
cofactors in the kidney tubules and parathy-
roid cells that modulate the downstream 
pathway to produce a variable phenotype 
and clinical outcome. Furthermore, as 
the studied phenotype is a 24-hour urine 
calcium concentration — representing a 
summation of the eff ect of CaR on diff er-
ent segments of the kidney tubules as well 
as other non-CaR-mediated factors such 
as dietary calcium intake and vitamin D 
status — the actual eff ect of 990G on distal 
tubular calcium absorption may be diffi  -
cult to detect.
With the recent advances in genetic 
epidemiology and bioinformatics, a bet-
ter understanding of the pathogenesis of 
common disorders as well as a more accu-
rate prediction of treatment responses is 
possible. Preliminary studies in end-stage 
renal failure patients have pointed to an 
improved response in carriers of 990G 
to the calcimimetic drug cinacalcet in 
terms of PTH suppression.12 It remains 
to be confi rmed whether an inhibitory 
agent that specifi cally targets position 990 
would reduce hypercalciuria and inhibit 
renal stone formation.
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Figure 1 | Schematic diagram of the calcium-sensing receptor with highlights of the 
activation and inactivation mutations and the functional single-nucleotide polymorphisms.
